UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Moving in Measure: Essays in honour of Brian Moloney

Italian studies, 1990-01, Vol.45 (1), p.118-157

1990

Volltextzugriff (PDF)

Resolution and b value dependent structural connectome in ex vivo mouse brain

NeuroImage (Orlando, Fla.), 2022-07, Vol.255, p.119199-119199, Article 119199

2022

Volltextzugriff (PDF)

EFFICACY OF REVEFENACIN, A LONG-ACTING MUSCARINIC ANTAGONIST FOR NEBULIZED THERAPY, IN COPD PATIENTS WITH MARKERS OF MORE SEVERE DISEASE

Chest, 2018-10, Vol.154 (4), p.736A-737A

2018

Volltextzugriff (PDF)

IMPROVEMENTS IN HEALTH STATUS WITH REVEFENACIN: A POST HOC ANALYSIS OF ST GEORGE’S RESPIRATORY QUESTIONNAIRE IN PATIENT SUBGROUPS FROM REPLICATE PHASE 3 TRIALS

Chest, 2020-10, Vol.158 (4), p.A1750-A1751

2020

Volltextzugriff (PDF)

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Respiratory research, 2019-10, Vol.20 (1), p.241-10, Article 241

2019

Volltextzugriff (PDF)

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study

International journal of chronic obstructive pulmonary disease, 2014-01, Vol.9 (default), p.745-751

2014

Volltextzugriff (PDF)

A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD

Respiratory medicine, 2012-07, Vol.106 (7), p.970-979

2012

Volltextzugriff (PDF)

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

BMC pulmonary medicine, 2020-05, Vol.20 (1), p.134-10, Article 134

2020

Volltextzugriff (PDF)

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

Respiratory medicine, 2019-07, Vol.153, p.38-43

2019

Volltextzugriff (PDF)

Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial

PloS one, 2012-12, Vol.7 (12), p.e50716

2012

Volltextzugriff (PDF)

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials

Therapeutic advances in respiratory disease, 2020, Vol.14, p.1753466620905278-1753466620905278

2020

Volltextzugriff (PDF)

The 24-Hour Profile of FEV 1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

Chest, 2017-10, Vol.152 (4), p.A770

2017

Volltextzugriff (PDF)

The 24-Hour Profile of FEV1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

Chest, 2017-10, Vol.152 (4), p.A770-A770

2017

Volltextzugriff (PDF)

Improvements in Health Status With Revefenacin, a Once-Daily Long-Acting Muscarinic Antagonist for Nebulization: Changes in St George’s Respiratory Questionnaire and COPD Assessment Test in Replicate 3-Month Studies

Chest, 2017-10, Vol.152 (4), p.A819-A819

2017

Volltextzugriff (PDF)

Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials

Pulmonary pharmacology & therapeutics, 2019-08, Vol.57, p.101808-101808, Article 101808

2019

Volltextzugriff (PDF)

Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study

The Lancet (British edition), 2005-07, Vol.366 (9481), p.211-217

2005

Volltextzugriff (PDF)

Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire

Mayo Clinic proceedings, 2011-05, Vol.86 (5), p.375-381

2011

Volltextzugriff (PDF)

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease

Data in brief, 2019-10, Vol.26, p.104277-104277, Article 104277

2019

Volltextzugriff (PDF)

Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD

Chest, 2011-10, Vol.140 (4), p.1043A-1043B

2011

Volltextzugriff (PDF)

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study

International journal of chronic obstructive pulmonary disease, 2014-01, Vol.9, p.745

2014

Volltextzugriff (PDF)

Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes: Monitoring and Actualization of Noetic Training (MANTRA) feasibility pilot

The American heart journal, 2001-11, Vol.142 (5), p.760-769

2001

Volltextzugriff (PDF)

Beneficial Effects of Noetic Therapies on Mood Before Percutaneous Intervention for Unstable Coronary Syndromes

Nursing research (New York), 2004-03, Vol.53 (2), p.116-121

2004

Volltextzugriff (PDF)

Applications of two-body Dirac equations to the meson spectrum with three versus two covariant interactions, SU(3) mixing, and comparison to a quasipotential approach

Physical review. D, Particles, fields, gravitation, and cosmology, 2010-11, Vol.82 (9), Article 094020

2010

Volltextzugriff (PDF)

Correlations Between Preprocedure Mood and Clinical Outcome in Patients Undergoing Coronary Angioplasty

Cardiology in review, 2003-11, Vol.11 (6), p.309-317

2003

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(25)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(16)
Life Sciences & Biomedicine
(14)
Humans
(12)
Male
(10)
Middle Aged
(10)
Aged
(9)
Female
(9)
Respiratory System
(8)
Chronic Obstructive Pulmonary Disease
(7)
Double-Blind Method
(6)
Adult
(5)
Chronic Obstructive Lung Disease
(5)
Muscarinic Antagonists - Administration & Dosage
(5)
Revefenacin
(5)
Treatment Outcome
(5)
Aged, 80 And Over
(4)
Biological And Medical Sciences
(4)
Drug Dosages
(4)
Lung Diseases
(4)
Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Moving in Measure: Essays in honour of Brian Moloney

Resolution and b value dependent structural connectome in ex vivo mouse brain

EFFICACY OF REVEFENACIN, A LONG-ACTING MUSCARINIC ANTAGONIST FOR NEBULIZED THERAPY, IN COPD PATIENTS WITH MARKERS OF MORE SEVERE DISEASE

IMPROVEMENTS IN HEALTH STATUS WITH REVEFENACIN: A POST HOC ANALYSIS OF ST GEORGE’S RESPIRATORY QUESTIONNAIRE IN PATIENT SUBGROUPS FROM REPLICATE PHASE 3 TRIALS

Maintained therapeutic effect of revefenacin over 52 weeks in moderate to very severe Chronic Obstructive Pulmonary Disease (COPD)

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study

A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD

Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis

Revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy: Safety and tolerability results of a 52-week phase 3 trial in moderate to very severe chronic obstructive pulmonary disease

Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial

Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials

The 24-Hour Profile of FEV 1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

The 24-Hour Profile of FEV1 After 12-Weeks Treatment With Revefenacin, a Once Daily Long-Acting Muscarinic Receptor Antagonists for Nebulization: A Spirometry Substudy

Improvements in Health Status With Revefenacin, a Once-Daily Long-Acting Muscarinic Antagonist for Nebulization: Changes in St George’s Respiratory Questionnaire and COPD Assessment Test in Replicate 3-Month Studies

Cardiovascular safety of revefenacin, a once-daily, lung-selective, long-acting muscarinic antagonist for nebulized therapy of chronic obstructive pulmonary disease: Evaluation in phase 3 clinical trials

Music, imagery, touch, and prayer as adjuncts to interventional cardiac care: the Monitoring and Actualisation of Noetic Trainings (MANTRA) II randomised study

Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK)

Prevalence of Airway Obstruction Assessed by Lung Function Questionnaire

Data on the safety and tolerability of revefenacin, in patients with moderate to very severe chronic obstructive pulmonary disease

Dose-Related Efficacy of GSK573719: A Long-Acting Muscarinic Receptor Antagonist (LAMA) With Sustained 24-Hour Activity in COPD

Characterization of airway inflammation in patients with COPD using fractional exhaled nitric oxide levels: a pilot study

Integrative noetic therapies as adjuncts to percutaneous intervention during unstable coronary syndromes: Monitoring and Actualization of Noetic Training (MANTRA) feasibility pilot

Beneficial Effects of Noetic Therapies on Mood Before Percutaneous Intervention for Unstable Coronary Syndromes

Applications of two-body Dirac equations to the meson spectrum with three versus two covariant interactions, SU(3) mixing, and comparison to a quasipotential approach

Correlations Between Preprocedure Mood and Clinical Outcome in Patients Undergoing Coronary Angioplasty

Suchergebnisse filtern